Axsome Therapeutics (AXSM) Set to Post Earnings on Monday

Axsome Therapeutics (NASDAQ:AXSM) is anticipated to release its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect Axsome Therapeutics to post earnings of ($0.6342) per share and revenue of $249.19 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 2, 2026 at 8:00 AM ET.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Monday, August 10th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). The company had revenue of $218.38 million during the quarter, compared to analysts’ expectations of $221.11 million. Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. On average, analysts expect Axsome Therapeutics to post ($3.03) EPS for the current fiscal year and $3.51 EPS for the next fiscal year.

Axsome Therapeutics Trading Up 0.7%

NASDAQ:AXSM opened at $144.43 on Friday. The company has a quick ratio of 1.34, a current ratio of 1.43 and a debt-to-equity ratio of 1.52. Axsome Therapeutics has a fifty-two week low of $123.50 and a fifty-two week high of $260.19. The firm’s 50 day moving average is $184.76 and its two-hundred day moving average is $198.93.

Insider Activity at Axsome Therapeutics

In other news, COO Mark L. Jacobson sold 10,000 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total value of $2,086,500.00. Following the completion of the sale, the chief operating officer owned 10,000 shares of the company’s stock, valued at $2,086,500. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Herriot Tabuteau sold 4,660 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $213.95, for a total transaction of $997,007.00. Following the completion of the transaction, the chief executive officer directly owned 7,229 shares in the company, valued at approximately $1,546,644.55. This represents a 39.20% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 59,664 shares of company stock valued at $12,624,805. 20.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

AXSM has been the subject of several research reports. Zacks Research raised shares of Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 18th. Wells Fargo & Company increased their target price on Axsome Therapeutics from $255.00 to $256.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 11th. Piper Sandler reduced their target price on Axsome Therapeutics from $258.00 to $238.00 and set an “overweight” rating on the stock in a report on Monday, October 26th. BMO Capital Markets began coverage on Axsome Therapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $310.00 target price on the stock. Finally, Guggenheim boosted their price target on Axsome Therapeutics from $260.00 to $275.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $274.68.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company develops medicines for conditions with significant unmet medical needs, including depression, narcolepsy, excessive daytime sleepiness, and other neurological disorders.

Axsome’s commercial products include Auvelity (dextromethorphan and bupropion), an oral treatment approved in the United States for major depressive disorder in adults, and Sunosi (solriamfetol), a therapy for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.